Immunotherapy Progress in the Treatment of CRC

In an interview with Targeted Oncology, Paul Richardson, MD, highlighted his presentation from the 4th Annual Miami Cancer Institute Global Summit on Immunotherapies for Hematologic Malignancies on updates and personalization of treatments for patients with multiple myeloma.

In season 4, episode 1 of Targeted Talks, Benjamin L. Schlechter, MD, discuses new studies in the gastrointestinal cancers space.

FDA approval may be looming for the combination of zolbetuximab and capecitabine/oxaliplatin after primary phase 3 results were presented during the March ASCO Virtual Plenary.

In season 2, episode 6 of Targeted Talks, Dr. Michael J. Overman, joins Targeted Oncology for a special discussion around rare genomic alterations in colorectal cancer

Ripretinib will be evaluated in a phase 3 trial for patients with gastrointestinal stromal tumor after being added to the NCCN guidelines and receiving 2 breakthrough therapy designations from the FDA.

In an interview with Targeted Oncology, Christopher Chambers, MD, discussed how primary care physicians are involved with the diagnosis of cancer and the challenges faced with early detection.